Edison Publishes Report on BB Biotech (BION)

London, United Kingdom–(Newsfile Corp. – August 14, 2024) – Edison publishes report on BB Biotech (SWX: BION).

BB Biotech, a Swiss-based investment firm, focuses on long-term capital growth of biotechnology companies developing and commercializing innovative medicines. At least 90% of the portfolio is held by listed companies, primarily companies with products on the market or promising drug candidates in late-stage development. BION is benchmarked against the Nasdaq Biotech Index (in CHF), but is managed on a bottom-up basis, with a focused c 20-35 stock portfolio.

Click here to read the full report.

All reports published by Edison are available for free download from the website
www.edisongroup.com.

Edison is authorized and regulated by the Financial Conduct Authority.

Edison is not an advisor or broker-dealer and does not offer investment advice. Edison’s reports are not solicitations to buy or sell securities.

Contact Edison via:

LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv

To view the source version of this press release, visit https://www.newsfilecorp.com/release/219911

SOURCE: Edison Group